Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Debunking Myths in the US Healthcare System
Your Article Summary
See Latest ArticlesTransdermal buprenorphine – a critical appraisal of its role in pain management
Journal of Pain Research, 09/16/09
Hans G et al. – This review paper focuses almost entirely on the clinical experience concerning the transdermal administration of buprenorphine, although preclinical aspects are also addressed in order to provide a complete picture of the unique pharmacological properties of this analgesic drug. Mounting evidence indicates the appropriateness of BUP TDS in the treatment of diverse acute and chronic pain syndromes which have been less or not responsive to other opioids. Additionally, BUP TDS seems to hold great promise for other difficult–to–treat (pain) conditions, such as patients in the intensive care setting. However, its use is somewhat tempered by the occurrence of local skin reactions which have been shown to be often therapy resistant.
Guy Hans, 09/17/09
| The transdermal administration of buprenorphine has some highly interesting clinical features. First of all, it shows excellent pain relief in many different types of pain (like nociceptive but also neuropathic pain which is sometimes more resistant to other general analgesics). It is also very useful for the (long-term) treatment of cancer pain. In addition, transdermal buprenorphine carries a lesser risk for the development of respiratory depression than other opioids, making it safer to use in patients suffering from severe pain. Its use is however somewhat limited by the occurrence of skin reactions which are sometimes difficult to treat. Finally, the unique pharmacological properties of buprenorphine, make this drug suitable for use in specific - difficult to treat - clinical settings, like patients on intensive care (who are often difficult to treat due to the prolonged administration of iv opioids) and post-trauma patients who need good quality of analgesia during the revalidation without sedation or other central side effects. Further large-scale studies on transdermal buprenorphine in these specific clinical settings should be considered. |
Related Articles
The Use of Transdermal Fentanyl in Cancer Pain: A Compliance Study of Outpatients in Taiwan
American Journal of Hospice and Palliative Medicine, 10/05/09
Relevance Score: 80%
Transdermal Fentanyl: Pharmacology and Toxicology
Journal of Medical Toxicology, 11/02/09
Relevance Score: 78%
Absence of pain with hyperhidrosis: A new syndrome where vascular afferents may mediate cutaneous sensation
Pain, 10/19/09
Relevance Score: 69%
Pain among Veterans of Operations Enduring Freedom and Iraqi Freedom: Do Women and Men Differ?
Pain Medicine, 10/13/09
Relevance Score: 69%
Physical interventions and injection techniques for reducing injection pain during routine childhood immunizations: Systematic review of randomized controlled trials and quasi-randomized controlled trials
Clinical Therapeutics, 10/16/09
Relevance Score: 68%
Today in Pain Management...keeping you current
Receive free subspecialty "5-minute updates" via email
Chest pain in a young basketball player
Journal of General Internal Medicine, 12/07/09
Examination of musculoskeletal chest pain - An inter-observer reliability study
Manual Therapy , 12/07/09
Economic Evaluation of Pharmacotherapy of Migraine Pain: A Review of the Literature
Journal Of Pain & Palliative Care Pharmacotherapy, 12/02/09
Sponsor
Article Search
Sponsor